Faron Pharmaceuticals Oy
Company Profile
Business description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Contact
Joukahaisenkatu 6 B
Turku20520
FINT: +358 24695151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
stocks
New ASX share added to our best ideas
stocks
Fair value downgraded for ASX heavyweight
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,240.30 | 42.60 | 0.46% |
CAC 40 | 8,075.76 | 108.81 | 1.37% |
DAX 40 | 24,449.08 | 335.46 | 1.39% |
Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
FTSE 100 | 9,453.25 | 6.82 | 0.07% |
HKSE | 27,287.12 | 431.56 | 1.61% |
NASDAQ | 22,755.16 | 95.15 | 0.42% |
Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
S&P 500 | 6,711.20 | 22.74 | 0.34% |
S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |